Synthesis and biological evaluation of matrine derivatives containing benzo-α-pyrone structure as potent anti-lung cancer agents

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wu, Lichuan ^a   Wang, Guizhen ^b   Liu, Shuaibing ^a   Wei, Jinrui ^c   Zhang, Sen ^a   Li, Ming ^d   Zhou, Guangbiao ^b   Wang, Lisheng ^a  

^a GUANGXI UNIVERSITY   (China)

^b INSTITUTE OF ZOOLOGY   (China)

^c GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

^d KUNMING INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; MATRINE; PYRONE DERIVATIVE; QUINOLIZINE DERIVATIVE;

A-549 CELL LINE; ANIMAL; AUTOPHAGY; CELL PROLIFERATION; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG TUMOR; METABOLISM; MOUSE; PATHOLOGY; PRECLINICAL STUDY; SCID MOUSE; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

A549 CELLS; ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, SCID; PYRONES; QUINOLIZINES; SIGNAL TRANSDUCTION; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84992561381     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35918     Document Type: Article

References (37)

1. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer. WHO Press, 2015. Adv Nutr 7, 418-419 (2016).
2. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N Engl J Med 359, 1367-1380 (2008).
3. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 (2004).
4. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
5. Guan, C. N., Cai, L. Z., Yue, L. Q. & Zhang, Y. Clinical study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy. Zhongguo Zhong Yao Za Zhi 31, 510-512 (2006).
6. Liu, J. & Liu, Y. Influence of erbanxiao solution on inhibiting angiogenesis in stasis toxin stagnation of non-small cell lung cancer. J Tradit Chin Med 33, 303-306 (2013).
7. Sun, M. et al. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med 2012, 373219 (2012).
8. Sun, Q. et al. Meta-analysis: therapeutic effect of transcatheter arterial chemoembolization combined with compound kushen injection in hepatocellular carcinoma. Afr J Tradit Complement Altern Med 9, 178-188 (2012).
9. Wang, C. Y., Bai, X. Y. & Wang, C. H. Traditional Chinese medicine: a treasured natural resource of anticancer drug research and development. Am J Chin Med 42, 543-559 (2014).
10. Wei, R. et al. Efficacy of Yanshu injection (a compound Chinese traditional medicine) combined with concurrent radiochemotherapy in patients with stage III nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi 33, 391-394 (2011).
11. Liu, Y. et al. Anti-tumor activities of matrine and oxymatrine: literature review. Tumour Biol 35, 5111-5119 (2014).
12. Wu, L. et al. Synthesis and biological evaluation of matrine derivatives as anti-hepatocellular cancer agents. Bioorg Med Chem Lett 26, 4267-4271 (2016).
13. Hu, P. Y. et al. Pharmacokinetics and distribution of sophoridine nanoliposomes in rats. Chinese Journal of New Drugs 21, 2662-2666 (2012).
14. Li, Y. et al. High-performance liquid chromatographic method for simultaneous determination of sophoridine and matrine in rat plasma. Biomed Chromatogr 18, 619-624 (2004).
15. Ye, G. et al. LC-MS characterization of efficacy substances in serum of experimental animals treated with Sophora flavescens extracts. Biomed Chromatogr 21, 655-660 (2007).
16. Wang, L. et al. Synthesis, characterization and in vitro anti-tumor activities of matrine derivatives. Bioorg Med Chem Lett 22, 4100-4102 (2012).
17. Lacy, A. & O'Kennedy, R. Studies on coumarins and coumarin-related compounds to determine their therapeutic role in the treatment of cancer. Curr Pharm Des 10, 3797-3811 (2004).
18. Levine, B. Cell biology: autophagy and cancer. Nature 446, 745-747 (2007).
19. Nys, K., Agostinis, P. & Vermeire, S. Autophagy: a new target or an old strategy for the treatment of Crohn's disease? Nature reviews. Gastroenterology & hepatology 10, 395-401 (2013).
20. Fresno Vara, J. A. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30, 193-204 (2004).
21. Liu, J. Y. et al. Effect of matrine on the expression of substance P receptor and inflammatory cytokines production in human skin keratinocytes and fibroblasts. Int Immunopharmacol 7, 816-823 (2007).
22. Jiang, H. et al. Matrine upregulates the cell cycle protein E2F-1 and triggers apoptosis via the mitochondrial pathway in K562 cells. Eur J Pharmacol 559, 98-108 (2007).
23. Li, H. et al. Therapeutic effects of matrine on primary and metastatic breast cancer. Am J Chin Med 38, 1115-1130 (2010).
24. Liu, T., Song, Y., Chen, H., Pan, S. & Sun, X. Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull 33, 1740-1745 (2010).
25. Chen, J. et al. Effects of matrine injection on T-lymphocyte subsets of patients with malignant tumor after gamma knife radiosurgery. Journal of Chinese integrative medicine 4, 78-79 (2006).
26. Huang, S., Fan, W., Liu, P. & Tian, J. Meta analysis of compound matrine injection combined with cisplatin chemotherapy for advanced gastric cancer. Zhongguo Zhong Yao Za Zhi 36, 3198-3202 (2011).
27. Metro, G. & Crino, L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res 1, 5-13 (2012).
28. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101, 13306-13311 (2004).
29. Sharma, S. V., Bell, D. W., Settleman, J. & Haber, D. A. Epidermal growth factor receptor mutations in lung cancer. Nature reviews. Cancer 7, 169-181 (2007).
30. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792 (2005).
31. Tian, X. et al. Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett 16, 1721-1725 (2006).
32. DeWit, M. A. & Gillies, E. R. Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as selfimmolative spacers. Org Biomol Chem 9, 1846-1854 (2011).
33. Greene's protective groups in organic synthesis. Choice: Current Reviews for Academic Libraries 44, 1562-1562 (2007).
34. Chun, K. et al. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem 16, 530-535 (2008).
35. Wu, L. et al. Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway. Oncol Rep 34, 3311-3317 (2015).
36. Wu, L. C. et al. Largazole arrests cell cycle at G1 phase and triggers proteasomal degradation of E2F1 in lung cancer cells. Acs Med Chem Lett 4, 921-926 (2013).
37. Zhou, G. B. et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109, 3441-3450 (2007).